Oral Anticoagulation in Haemodialysis Patients

Inclusion Criteria: * Adult patients (≥ 18 years) * Patient on hemodialysis treatment for at least 1 month * Patient with a history of, or presenting a new episode of atrial fibrillation (either permanent or paroxysmal). * Patient with a CHADS2VASC score ≥2 * Patient with high risk of bleeding as defined by (1) HASBLED score ≥3 OR (2) HASBLED ≥ CHADS2VASC score, OR (3) recent history of severe bleeding (type 3a, 3b, 3c), particularly cerebral or gastrointestinal, OR (4) prior recurrent (\>2) history of falls. * Patient capable of understanding information about the study and of giving his/her consent * Patient informed of the preliminary medical exam results * Patient with healthcare insurance * Written consent signed Exclusion Criteria: * Formal indication to oral anticoagulation beside atrial fibrillation (mechanic heart valves, recurrent thrombophlebitis, antiphospholipid syndrome) * Life expectancy \< 6 months (e.g., terminal cancer) * Live donor transplantation scheduled within 6 months * Pregnancy (β-HCG blood-based assay)or nursing (lactating) women * Women of child bearing potential, unless they are using an effective method of birth control * Patient under legal guardianship * Patients under law protection * Known hypersensibility to coumadin or indoine derivatives or to any excipients (CI to oral AVK) * Severe liver failure (CI to oral AVK)